CURLF · Curaleaf Holdings, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 5, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 5, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $133.5M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 20.1% | Six Months Ended June 30, 2026 | — |
| Adjusted gross profit from continuing operations non-GAAP | $327.9M | Six Months Ended June 30, 2026 | — |
| Adjusted gross profit margin from continuing operations non-GAAP | 49.4% | Six Months Ended June 30, 2026 | — |
| Capital expenditures | $32.9M | Six Months Ended June 30, 2026 | — |
| Florida dispensaries | 73 | Second Quarter 2026 | — |
| Free cash flow from continuing operations non-GAAP | $17.39M | six months ended June 30, 2026 | — |
| Shares retired and repurchased | 1.01M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CURLF
this stock
Curaleaf Holdings, Inc.
|
$2.59B | — | -5.0% | — | 0.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.22B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +2.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.77B | +0.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 5, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CURLF | -3.8% | +13.2% | — | +7.1% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -3.4% | +8.1% | — | +4.6% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.